Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source:

Gasparetto C, et al. Abstract 8038. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
June 24, 2021
1 min watch
Save

VIDEO: Selinexor combination highly active in heavily pretreated multiple myeloma

Source:

Gasparetto C, et al. Abstract 8038. Presented at: ASCO Annual Meeting; June 4-8, 2021 (virtual meeting).

Disclosures: Gasparetto reports leadership fees from Celgene; consulting/advising for AbbVie/Genentech, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi; speakers’ fees from GlaxoSmithKlinem Karyopharm Therapeutics, Sanofi; and travel expenses from Celgene and Karyopharm Therapeutics
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Once weekly selinexor, carfilzomib and dexamethasone was highly active and yielded deep responses in patients with heavily pretreated multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

“In patients that we treated at the recommended phase 2 dose, we achieved a response, which was kind of impressive, close to 80% and we had one-third of patients achieving a very good partial response,” Cristina Gasparetto, MD, director of the multiple myeloma program at Duke University, told Healio in a video interview.